KalVista Pharmaceuticals (KALV) Gains from Investment Securities (2014 - 2015)

KalVista Pharmaceuticals (KALV) reported Gains from Investment Securities of -$2000.0 for Q2 2015, up 99.61% sequentially from -$518000.0 in Q1 2015.

KalVista Pharmaceuticals (KALV) Gains from Investment Securities (2014 - 2015) Analysis & Trends

KalVista Pharmaceuticals (KALV) has 2 years of Gains from Investment Securities data on file, last reported at -$2000.0 in Q2 2015.

For the quarter ending Q2 2015, Gains from Investment Securities changed N/A year-over-year to -$2000.0; the trailing twelve-month figure through Dec 2015 stood at -$520000.0 (changed N/A YoY), and the FY2015 full-year result was -$520000.0, down 185.95% from the prior year.
Gains from Investment Securities grew to -$2000.0 in Q2 2015, from -$518000.0 in the prior quarter.
In the past five years, Gains from Investment Securities ranged from a high of $338000.0 in Q4 2014 to a low of -$518000.0 in Q1 2015.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn
7	Belite Bio	62.72 Bn	62.72 Bn	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn
9	Revolution Medicines	37.35 Bn	37.35 Bn	-
10	KalVista Pharmaceuticals	1.36 Bn	1.36 Bn	49.41 Mn

Download Data